Premium
Therapy‐induced drug resistance in a human leukemia line (LALW‐2)
Author(s) -
White Les,
Haber Michelle,
Brian Michael J.,
Norris Murray D.,
Trickett Annette,
Sosula Leo,
Tiley Campbell,
Stewart Bernard W.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890601)63:11<2103::aid-cncr2820631106>3.0.co;2-n
Subject(s) - medicine , drug resistance , leukemia , drug , pharmacology , oncology , microbiology and biotechnology , biology
A human leukemic T‐cell line, LALW‐2, established by xenografting in nude mice, has been maintained through 14 serial passages. The cells display consistent morphologic features, immunophenotype, and karyotypic aberrations (including an 11;14 translocation) and exhibit rearrangement of the T‐cell receptor β‐chain gene. The growth rate of LALW‐2 xenografts was differentially affected by drugs administered to host mice, the cells being resistant to cytotoxic agents (particularly methotrexate and doxorubicin) used in treatment of the donor patient. In short‐term in vitro culture, LALW‐2 cells exhibited extreme resistance to methotrexate and were also resistant to vincristine, vinblastine, dactinomycin, and doxorubicin. The findings differ from those obtained with laboratory‐derived methotrexate or multidrug‐resistant cell lines. The response of LALW‐2 cells, in both the nude mouse model and in vitro , is consistent with aquisition of drug‐resistance as a result of clinical treatment.